Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Flu, COVID-19 and RSV are predicted to cause about as many hospitalizations as last year. Houston experts offer tips for ...

The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...

The vaccine is recommended for use only in the run-up to RSV season. It's time for RSV, flu, and COVID shots, and the CDC has ...

The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the most-severe effects of respiratory syncytial virus (RSV).

Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory ...

RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...

In 2023, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended ...

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

Researchers from Brigham and Women’s Hospital published new research in Science Translational Medicine showing that natural ...